Benoit Leduc

Voyageur Pharmaceuticals would like to engage with the Government of Canada to explore federal programs, grants, and investment incentives that would support the company's continued operations and growth in Alberta. Discussion may include opportunities to enhance the competitiveness of the company's Canadian footprint and to identify federal measures that would help retain jobs, innovation capacity, and long-term investment in Canada.

Strengthening Canada’s health workforce including promoting health workforce safety. Advancing adoption of AI in the healthcare and health research sectors. Improving Canada’s physical and digital infrastructure for both health research and healthcare delivery. Federal role in the health system as it relates to funding, the use of federal spending power, and pan-Canadian priorities, including in the areas of aging, older adult care, child and youth health, mental health and substance use, palliative care, Indigenous health, public health, and data. Advancing Canada’s health research and innovation agenda as it relates to funding, policy and program design, and regulatory matters, including in the areas of clinical trials and development of innovative medical treatments.

Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats. Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Seek funding support from the Strategic Innovation Fund to expand Emergent's Winnipeg facility. Discuss changes to take home naloxone program. Eligibility for Scientific Research and Experimental Development tax incentives. Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats.

Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats. To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Eligibility for Scientific Research and Experimental Development tax incentives. Discuss changes to take home naloxone program. Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. Seek funding support from the Strategic Innovation Fund to expand Emergent's Winnipeg facility.

Free trade agreements as they relate to biomanufacturing industry in Canada Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission. Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Support the establishment of a life sciences strategy in Canada Advocate in support of a pan-Canadian school food program. Advocate for the implementation of a federal diabetes and obesity strategy. Advocate for the establishment of public-private partnerships to support chronic disease prevention.

promote innovations in medical technologies (equipment, services and digital solutions) that support better care for more people across Canada. This includes mobile and virtual solutions which can improve access to care in rural and remote regions of the country, while reducing costs and environmental impacts.

Discussions on how the Government of Canada work collaboratively with provincial and territorial governments to commit to a long-term federal funding strategy to ensure that adult vaccines recommended for use by the National Advisory Committee on Immunizations are publicly funded and universally accessible across all jurisdictions. Discussions on the renewal of the National Immunization Strategy to bolster public vaccination programs across Canada. Discussions on strengthening Canada’s adult immunization programs, as access to adult vaccines remains inconsistent, inequitable and underfunded throughout the country.

Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments. The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada. Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally. Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic. Public policy issues related to Health Canada's review of NCE Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry. Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada. Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices. National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians. Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process. Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage. Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Supporting the company in seeking government funding for medical isotope production.

Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB). Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.